Diabetes Care, Vol 20, Issue 3 330-335, Copyright © 1997 by American Diabetes Association

ARTICLES

A prospective study of oral contraceptives and NIDDM among U.S. women

L Chasan-Taber, WC Willett, MJ Stampfer, DJ Hunter, GA Colditz, D Spiegelman and JE Manson
Channing Laboratory, Brigham and Women's Hospital, Boston, Massachusetts, USA. phlec@gauss.bwh.harvard.edu

OBJECTIVE: To examine prospectively the association between modern oral contraceptives with low doses of estrogen and progestin and subsequent incidence of NIDDM. RESEARCH DESIGN AND METHODS: In a prospective cohort study, 98,590 U.S. female nurses aged 25 to 42 and free of diagnosed diabetes, coronary heart disease, stroke, and cancer at baseline in 1989 were followed for 4 years. Endpoint was incidence of confirmed NIDDM. Oral contraceptive use was reported on mailed questionnaires. RESULTS: During 352,067 person-years follow-up, we confirmed 185 incident cases of NIDDM. After adjusting for age, BMI, cigarette smoking, family history of diabetes, parity, physical activity, alcohol intake, ethnicity, history of diagnosis of infertility, elevated cholesterol, and hypertension, women currently using oral contraceptives had a relative risk (RR) of 1.6 (95% CI, 0.9-3.1). For past users, the multivariate RR was 1.2 (95% CI, 0.8-1.8). This association was attenuated after restricting the analysis to symptomatic cases of NIDDM. For current users, RR = 1.3 (95% CI, 0.6-2.8), and for past users, RR = 0.9 (95% CI, 0.6-1.4), suggesting that increased surveillance may explain at least part of any excess risk. CONCLUSIONS: In this large prospective study, we found no appreciable increase in the 4-year risk of NIDDM among current users of oral contraceptives. There was no apparent increase in risk among past users. The small number of cases reflect the low absolute risk of NIDDM in this population of young women.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Blitshteyn, J. E. Crook, and K. A. Jaeckle Is There an Association Between Meningioma and Hormone Replacement Therapy? J. Clin. Oncol., January 10, 2008; 26(2): 279 - 282. [Abstract] [Full Text] [PDF]

				P. Damm, E. R. Mathiesen, K. R. Petersen, and S. Kjos Contraception After Gestational Diabetes Diabetes Care, July 1, 2007; 30(Supplement_2): S236 - S241. [Full Text] [PDF]

				M. M. Hedderson, A. Ferrara, M. A. Williams, V. L. Holt, and N. S. Weiss Androgenicity of Progestins in Hormonal Contraceptives and the Risk of Gestational Diabetes Mellitus Diabetes Care, May 1, 2007; 30(5): 1062 - 1068. [Abstract] [Full Text] [PDF]

				S. Nader and E. Diamanti-Kandarakis Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis Hum. Reprod., February 1, 2007; 22(2): 317 - 322. [Abstract] [Full Text] [PDF]

				J. Vrbikova and D. Cibula Combined oral contraceptives in the treatment of polycystic ovary syndrome Hum. Reprod. Update, May 1, 2005; 11(3): 277 - 291. [Abstract] [Full Text] [PDF]

				L. Morin-Papunen, K. Rautio, A. Ruokonen, P. Hedberg, M. Puukka, and J. S. Tapanainen Metformin Reduces Serum C-Reactive Protein Levels in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4649 - 4654. [Abstract] [Full Text] [PDF]

				E. Diamanti-Kandarakis, J.-P. Baillargeon, M. J. Iuorno, D. J. Jakubowicz, and J. E. Nestler A Modern Medical Quandary: Polycystic Ovary Syndrome, Insulin Resistance, and Oral Contraceptive Pills J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1927 - 1932. [Full Text] [PDF]

				Z. T. Bloomgarden American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome: 25-26 August 2002, Washington, DC Diabetes Care, April 1, 2003; 26(4): 1297 - 1303. [Full Text] [PDF]

				L. Morin-Papunen, I. Vauhkonen, R. Koivunen, A. Ruokonen, H. Martikainen, and J. S. Tapanainen Metformin Versus Ethinyl Estradiol-Cyproterone Acetate in the Treatment of Nonobese Women with Polycystic Ovary Syndrome: A Randomized Study J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 148 - 156. [Abstract] [Full Text] [PDF]

				J. E. Nestler Should patients with polycystic ovarian syndrome be treated with metformin?: An enthusiastic endorsement Hum. Reprod., August 1, 2002; 17(8): 1950 - 1953. [Abstract] [Full Text] [PDF]

				C. Kim, D. S. Siscovick, S. Sidney, C. E. Lewis, C. I. Kiefe, and T. D. Koepsell Oral Contraceptive Use and Association With Glucose, Insulin, and Diabetes in Young Adult Women: The CARDIA Study Diabetes Care, June 1, 2002; 25(6): 1027 - 1032. [Abstract] [Full Text] [PDF]

				C. G. Solomon, F. B. Hu, A. Dunaif, J. Rich-Edwards, W. C. Willett, D. J. Hunter, G. A. Colditz, F. E. Speizer, and J. E. Manson Long or Highly Irregular Menstrual Cycles as a Marker for Risk of Type 2 Diabetes Mellitus JAMA, November 21, 2001; 286(19): 2421 - 2426. [Abstract] [Full Text] [PDF]

				C. Kim, K. W. Seidel, E. A. Begier, and Y. S. Kwok Diabetes and Depot Medroxyprogesterone Contraception in Navajo Women Arch Intern Med, July 23, 2001; 161(14): 1766 - 1771. [Abstract] [Full Text] [PDF]